Pfizer (PFE) Other Accumulated Expenses (2009 - 2026)

Pfizer has disclosed Other Accumulated Expenses across 17 years of filings, most recently posting $20.1 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses changed 0.46% year-over-year to $20.1 billion; the TTM figure through Mar 2026 stood at $20.1 billion (changed 0.46% YoY), while the FY2025 annual figure was $19.4 billion, down 1.46% from the prior year.
• Other Accumulated Expenses rose to $20.1 billion in Q1 2026, from $19.4 billion in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PFE reached as high as $24.6 billion in Q2 2022 and fell as low as $16.1 billion in Q3 2023.
• The 5-year median for Other Accumulated Expenses is $19.7 billion (2024), against an average of $19.8 billion.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 92.08% — and 2023, when it slumped 32.49%.
• A 5-year view of Other Accumulated Expenses shows it stood at $22.6 billion in 2022, then decreased by 9.0% to $20.5 billion in 2023, then retreated by 3.98% to $19.7 billion in 2024, then slipped by 1.46% to $19.4 billion in 2025, then increased by 3.48% to $20.1 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $20.1 billion, $19.4 billion, and $19.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.